Bristol Myers Squibb reports two Phase 3 updates: stock pre-market at EUR 50.67
Published on 10/14/2026 at 07:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSClinical updates and calendar
- Bristol Myers Squibb posted two Phase 3 updates on October 12, 2026.
- Bristol Myers Squibb stock was at EUR 50.67 at 7:49 a.m. CEST on October 14, 2026, at Lang & Schwarz.
- Bristol Myers Squibb scheduled its third-quarter 2026 results conference call for October 29, 2026.
Bristol Myers Squibb stock was at EUR 50.67 at Lang & Schwarz at 7:49 a.m. CEST on October 14, 2026. The company’s investor-relations site listed two Phase 3 updates dated October 12, 2026.
Pre-market price
Lang & Schwarz showed a bid of EUR 50.51 and an ask of EUR 50.82. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Bristol Myers Squibb stock.
Recent company updates
On October 12, 2026, Bristol Myers Squibb listed positive topline results from the interim analysis of the Phase 3 ACTION-1 trial for RYZ101, RayzeBio’s radiopharmaceutical therapy, in patients with GEP-NETs. The same investor page listed a Phase 3 ALOFT-IPF trial evaluating admilparant in adults with idiopathic pulmonary fibrosis that met its primary endpoint.
Next scheduled event
Bristol Myers Squibb’s next listed event is its third-quarter 2026 results conference call on October 29, 2026, at 8:00 a.m. ET, according to the company’s investor-relations calendar.
Market context: Market report S&P 500.
